Chronic obstructive pulmonary disease (COPD) requires extensive treatment with multiple drug therapy.Due to its increasing prevalence and complications, it is rapidly becoming one of the world’s most serious health issues. It is necessary to treat the disease at the earliest with proper monitoring and evaluation of the therapy to prevent further progression and associated complications. Drug ut...

High yield synthesis of trans-[(Me(3)P)(OC)(3)Fe = BDur] (Dur, "Duryl" = 2,3,4,6-Me(4)C(6)H) is achieved by salt elimination and subsequent liberation of trimethylsilylbromide from K[Fe(CO)(3)(PMe(3))SiMe(3)] and Br(2)BDur.

BACKGROUND Cefepime, piperacillin-tazobactam and meropenem are among the broadest-spectrum and most expensive antimicrobials. AIM To evaluate guidelines for appropriate use of these drugs. METHODS We developed guidelines for use of these antibiotics, and conducted a two-phase drug utilization evaluation. We included all patients who received one of the study drugs during two 3-month periods...

OBJECTIVES This report describes the development process of a drug dosing database for ethical drugs approved by the Korea Food & Drug Administration (KFDA). The goal of this study was to develop a computerized system that supports physicians' prescribing decisions, particularly in regards to medication dosing. METHODS The advisory committee, comprised of doctors, pharmacists, and nurses from...

(150-200 words) Drug Use Evaluation (DUE) is recognized as an effective tool for detecting and improving drug use and to strengthen clinical pharmacy and patient care It is vital for almost all drugs most importantly for antibiotics for being the highly used drug in hospitals and community The objective of this study was to do drug utilization evaluation of antibiotics in dh uttarakashi. It was...

In the Call Letter, CMS encourages ACOs to find Part D plan sponsor partners through a request for proposal process. I do believe that ACOs have an incentive to work with PDPs to control medical costs, including preventing readmissions. However, ACOs have no incentive to work to appropriately manage Part D utilization and may have incentives to increase Part D utilization to prevent the use of ...

In this article the authors present population-level prevalence rates for 61 specific drug-related problems occurring in three State Medicaid programs (Maryland, Iowa, and Washington) from 1989 through 1996 and a fourth (Georgia) from 1994 through 1996. The findings represent the first application of a consistent drug utilization review (DUR) screener program to Medicaid data across States. The...